Climb Bio (NASDAQ:CLYM – Get Free Report) was upgraded by investment analysts at Guggenheim to a “strong-buy” rating in a report released on Monday,Zacks.com reports.
CLYM has been the subject of several other reports. BTIG Research restated a “buy” rating and issued a $19.00 target price on shares of Climb Bio in a report on Monday. Raymond James Financial started coverage on Climb Bio in a report on Tuesday, March 10th. They issued a “strong-buy” rating and a $25.00 target price for the company. HC Wainwright boosted their target price on Climb Bio from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Robert W. Baird set a $21.00 target price on Climb Bio in a report on Wednesday, May 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a report on Monday, April 20th. Four equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $21.64.
Get Our Latest Analysis on CLYM
Climb Bio Price Performance
Climb Bio (NASDAQ:CLYM – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.06. As a group, equities research analysts predict that Climb Bio will post -0.87 earnings per share for the current year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of Climb Bio during the fourth quarter worth approximately $43,000. Blair William & Co. IL acquired a new position in shares of Climb Bio during the fourth quarter worth approximately $44,000. Balyasny Asset Management L.P. acquired a new position in shares of Climb Bio during the fourth quarter worth approximately $57,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Climb Bio during the third quarter valued at approximately $29,000. Finally, AQR Capital Management LLC bought a new stake in shares of Climb Bio during the first quarter valued at approximately $27,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.
Climb Bio Company Profile
Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.
At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.
Featured Stories
- Five stocks we like better than Climb Bio
- Campbell’s Soup Stock: Deep Value and a 7% Dividend Yield
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
